ranibizumab-leyk
ranibizumab-leyk is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including NUFYMCO. Available dosage form: injection, solution.
Drug Details
- Generic Name
- ranibizumab-leyk
- Brand Names
- NUFYMCO
- Application Number
- BLA761473
- Sponsor
- Zydus Pharmaceuticals USA Inc.
- NDC Codes
- 2
- Dosage Forms
- INJECTION, SOLUTION
- Routes
- INTRAVITREAL
- Active Ingredients
- RANIBIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE NUFYMCO is indicated for the treatment of patients with: NUFYMCO, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)